Company intelligence / Profile preview

Cytopia

Richmond (Melbourne), Victoria, Australiacytopia.itch.io ↗

Ownership: Private
Development stage: Other

Overview

Cytopia developed novel small molecules, including a vascular disrupting agent (VDA) CYT997 (phase 2 for cancer) and JAK2 inhibitor CYT387 (ready for phase 1 in myeloproliferative disorders at the time of acquisition). Clinical results showed activity in solid tumors; further data post-acquisition resided with the acquirer[1][2][3][4].

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Partnerships

Novartis (collaboration: Novartis handled product development and commercialization for select programs; Cytopia retained co-promotion rights in Australia/New Zealand)[7]Cancer Therapeutics CRC Pty Ltd (academic/commercial consortium collaboration)[3]

Beyond the preview

Go deeper on Cytopia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytopia.

Explore the full profile